GLP-1 and MASH: When weight loss isn’t the whole story
Cell Metabolism · 2026-07 · 38 (7) · 1258-1260
DOI: 10.1016/j.cmet.2026.06.005 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Metabolism, 2026-07. Verfasst von Michelle T Long und 2 weiteren Autor:innen. Beteiligte Einrichtung: Novo Nordisk A/S, Bagsværd, Denmark; Department of Medicine, Section of Gastroenterology, Boston University Chobanian and Avedisian School of Medicin…. Hauptthemen laut MEDLINE: Weight Loss, Glucagon-Like Peptide 1, Fatty Liver. Die Arbeit nennt 9 Literaturangaben. Gefördert von: Novo Nordisk A/S.
Abstract (Originalsprache)
Metabolic dysfunction-associated steatohepatitis (MASH) remains a major unmet clinical challenge. A new study by Gonzalez-Rellan et al.1 shows that glucagon-like peptide 1 (GLP-1) receptors on intrahepatic sinusoidal endothelial cells are key mediators of semaglutide's weight loss-independent hepatoprotective effects, reframing our understanding of how GLP-1-based therapies act within the diseased liver.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Novo Nordisk A/S, Bagsværd, Denmark; Department of Medicine, Section of Gastroenterology, Boston University Chobanian and Avedisian School of Medicine, Boston, MA, USA.
- Novo Nordisk A/S, Bagsværd, Denmark.
- Novo Nordisk A/S, Bagsværd, Denmark. Electronic address: fikk@novonordisk.com.
Förderung
- Novo Nordisk A/S
Zitieren
APA
Long, M. T., Krarup, N., & Knop, F. K. (2026). GLP-1 and MASH: When weight loss isn’t the whole story. Cell Metabolism, 38(7), 1258-1260. https://doi.org/10.1016/j.cmet.2026.06.005
Vancouver
Long MT, Krarup N, Knop FK. GLP-1 and MASH: When weight loss isn’t the whole story. Cell Metabolism. 2026;38(7):1258-1260. doi:10.1016/j.cmet.2026.06.005
BibTeX
@article{Long2026,
author = {Long, Michelle T and Krarup, Niels and Knop, Filip K},
title = {GLP-1 and MASH: When weight loss isn’t the whole story},
journal = {Cell Metabolism},
year = {2026},
volume = {38},
number = {7},
pages = {1258--1260},
doi = {10.1016/j.cmet.2026.06.005}
}
EUVIMED